1 Marrie, R. A., Yu, N., Wei, Y., Elliott, L. & Blanchard, J. High rates of physician services utilization at least five years before multiple sclerosis diagnosis. Mult. Scler. 19, 1113–1119 (2013).

2 Hughes, A. M. et al. Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially. Clin. Exp. Immunol. 172, 466–474 (2013).

3 Hedstrom, A. K., Hillert, J., Olsson, T. & Alfredsson, L. Reverse causality behind the association between reproductive history and MS. Mult. Scler. 20, 406–411 (2014).

4 Nielsen, N. M. et al. Reproductive history and risk of multiple sclerosis. Epidemiology 22, 546–552 (2011).

5 Ascherio, A., Munger, K. L. & Lunemann, J. D. The initiation and prevention of multiple sclerosis. Nat. Rev. Neurol. 8, 602–612 (2012).

6 Lucas, R. M., Byrne, S. N., Correale, J., Ilschner, S. & Hart, P. H. Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener. Dis. Manag. 5, 413–424 (2015).

7 Sawcer, S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 131, 3118–3131 (2008).

8 van der Mei, I. et al. Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Mult. Scler. 22, 461–469 (2016).

9 O'Gorman, C., Lin, R., Stankovich, J. & Broadley, S. A. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology 40, 1–12 (2013).

10 Westerlind, H. et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 137, 770–778 (2014).

11 Westerlind, H. et al. Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. Eur. J. Hum. Genet. 23, 688–692 (2015).

12 Simpson, S. et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82, 1132–1141 (2011).

13 Gale, C. R. & Martyn, C. N. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47, 425–448 (1995).

14 Berg-Hansen, P. et al. Prevalence of multiple sclerosis among immigrants in Norway. Mult. Scler. 21, 695–702 (2015).

15 Ahlgren, C., Oden, A. & Lycke, J. A nationwide survey of the prevalence of multiple sclerosis in immigrant populations of Sweden. Mult. Scler. 18, 1099–1107 (2012).

16 Ahlgren, C., Lycke, J., Oden, A. & Andersen, O. High risk of MS in Iranian immigrants in Gothenburg, Sweden. Mult. Scler. 16, 1079–1082 (2010).

17 Montgomery, S. M., Lambe, M., Olsson, T. & Ekbom, A. Parental age, family size, and risk of multiple sclerosis. Epidemiology 15, 717–723 (2004).

18 van der Mei, I. A. et al. Human leukocyte antigen-DR15, low infant sibling exposure and multiple sclerosis: gene-environment interaction. Ann. Neurol. 67, 261–265 (2010).

19 Barnett, M. H., McLeod, J. G., Hammond, S. R. & Kurtzke, J. F. Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania. J. Neurol. 263, 792–798 (2016).

20 Koch-Henriksen, N. & Sorensen, P. S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 9, 520–532 (2010).

21 Westerlind, H. et al. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult. Scler. 20, 1578–1583 (2014).

22 Ponsonby, A. L. et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 78, 867–874 (2012).

23 Magyari, M., Koch-Henriksen, N., Pfleger, C. C. & Sorensen, P. S. Reproduction and the risk of multiple sclerosis. Mult. Scler. 19, 1604–1609 (2013).

24 Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37–47 (2015).

25 Roshanisefat, H., Bahmanyar, S., Hillert, J., Olsson, T. & Montgomery, S. Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis. Mult. Scler. 18, 1430–1436 (2012).

26 Sawcer, S. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219 (2011).

27 Brynedal, B. et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2, e664 (2007).

28 Beecham, A. H. et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353–1360 (2013).

29 Moutsianas, L. et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat. Genet. 47, 1107–1113 (2015).

30 Rothman, K. J., Greenland, S. & Walker, A. M. Concepts of interaction. Am. J. Epidemiol. 112, 467–470 (1980).

31 Rothman, K. J., Greenland, S. & Lash, T. L. (eds) in Modern Epidemiology. 3rd edn Ch. 3 pp. 71–83 (Lippincott Williams & Wilkins, 2008).

32 Hawkes, C. H. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult. Scler. 13, 610–615 (2007).

33 Handel, A. E. et al. Smoking and multiple sclerosis: an updated meta-analysis. PLoS ONE 6, e16149 (2011).

34 Hedstrom, A. K., Baarnhielm, M., Olsson, T. & Alfredsson, L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 73, 696–701 (2009).

35 Ghadirian, P., Dadgostar, B., Azani, R. & Maisonneuve, P. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can. J. Public Health 92, 281–285 (2001).

36 Salzer, J. et al. Smoking as a risk factor for multiple sclerosis. Mult. Scler. 19, 1022–1027 (2013).

37 Hedstrom, A. K., Baarnhielm, M., Olsson, T. & Alfredsson, L. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult. Scler. 17, 788–793 (2011).

38 Heydarpour, P. et al. Potential impact of air pollution on multiple sclerosis in Tehran, Iran. Neuroepidemiology 43, 233–238 (2014).

39 Barragan-Martinez, C. et al. Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis. PLoS ONE 7, e51506 (2012).

40 Hedstrom, A. et al. Smokers run increased risk of developing anti-natalizumab antibodies. Mult. Scler. 20, 1081–1085 (2013).

41 Hedstrom, A. K. et al. Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a. Mult. Scler. 20, 445–450 (2014).

42 Chinoy, H. et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann. Rheum. Dis. 71, 961–965 (2012).

43 Klareskog, L., Catrina, A. I. & Paget, S. Rheumatoid arthritis. Lancet 373, 659–672 (2009).

44 Hedstrom, A. K., Hillert, J., Olsson, T. & Alfredsson, L. Nicotine might have a protective effect in the etiology of multiple sclerosis. Mult. Scler. 19, 1009–1013 (2013).

45 Nizri, E. et al. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of TH1 and TH17 responses. J. Immunol. 183, 6681–6688 (2009).

46 Shan, M. et al. Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema. Sci. Transl. Med. 1, 4ra10 (2009).

47 Odoardi, F. et al. T cells become licensed in the lung to enter the central nervous system. Nature 488, 675–679 (2012).

48 Hedstrom, A. K. et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 134, 653–664 (2011).

49 Hedstrom, A. K. et al. Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk. Int. J. Epidemiol. 43, 1791–1798 (2014).

50 Briggs, F. B. et al. Smoking and risk of multiple sclerosis: evidence of modification by NAT1 variants. Epidemiology 25, 605–614 (2014).

51 Friese, M. A. & Fugger, L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 128, 1747–1763 (2005).

52 Friese, M. A. et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat. Med. 14, 1227–1235 (2008).

53 Dendrou, C. A., Fugger, L. & Friese, M. A. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15, 545–558 (2015).

54 Mustafa, M. et al. The major histocompatibility complex influences myelin basic protein 63-88-induced T cell cytokine profile and experimental autoimmune encephalomyelitis. Eur. J. Immunol. 23, 3089–3095 (1993).

55 Mustafa, M. et al. Protective influences on experimental autoimmune encephalomyelitis by MHC class I and class II alleles. J. Immunol. 153, 3337–3344 (1994).

56 Issazadeh, S., Kjellen, P., Olsson, T., Mustafa, M. & Holmdahl, R. Major histocompatibility complex-controlled protective influences on experimental autoimmune encephalomyelitis are peptide specific. Eur. J. Immunol. 27, 1584–1587 (1997).

57 Hedstrom, A. K., Olsson, T. & Alfredsson, L. Smoking is a major preventable risk factor for multiple sclerosis. Mult. Scler. 22, 1021–1026 (2016).

58 Sundstrom, P. & Nystrom, L. Smoking worsens the prognosis in multiple sclerosis. Mult. Scler. 14, 1031–1035 (2008).

59 Correale, J. & Farez, M. F. Smoking worsens multiple sclerosis prognosis: two different pathways are involved. J. Neuroimmunol. 281, 23–34 (2015).

60 Di Pauli, F. et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult. Scler. 14, 1026–1030 (2008).

61 Healy, B. C. et al. Smoking and disease progression in multiple sclerosis. Arch. Neurol. 66, 858–864 (2009).

62 Hernan, M. A. et al. Cigarette smoking and the progression of multiple sclerosis. Brain 128, 1461–1465 (2005).

63 Pittas, F. et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J. Neurol. 256, 577–585 (2009).

64 Manouchehrinia, A. et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 136, 2298–2304 (2013).

65 Zivadinov, R. et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 73, 504–510 (2009).

66 Manouchehrinia, A., Weston, M., Tench, C. R., Britton, J. & Constantinescu, C. S. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. J. Neurol. Neurosurg. Psychiatry 85, 1091–1095 (2014).

67 Ramanujam, R. et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol. 72, 1117–1123 (2015).

68 Handel, A. E. et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 5, e12496 (2010).

69 Sundstrom, P., Nystrom, M., Ruuth, K. & Lundgren, E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J. Neuroimmunol. 215, 102–107 (2009).

70 Sundqvist, E. et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun. 13, 14–20 (2012).

71 Levin, L. I., Munger, K. L., O'Reilly, E. J., Falk, K. I. & Ascherio, A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann. Neurol. 67, 824–830 (2010).

72 Ascherio, A. & Munger, K. L. EBV and autoimmunity. Curr. Top. Microbiol. Immunol. 390, 365–385 (2015).

73 Makhani, N. et al. Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult. Scler. 22, 385–388 (2016).

74 Zhou, Y. et al. Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. Mult. Scler. (2016).

75 Nielsen, T. R. et al. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult. Scler. 15, 431–436 (2009).

76 Hedstrom, A. K., Lima Bomfim, I., Hillert, J., Olsson, T. & Alfredsson, L. Obesity interacts with infectious mononucleosis in risk of multiple sclerosis. Eur. J. Neurol. 22, 578–e538 (2015).

77 Serafini, B. et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899–2912 (2007).

78 Lassmann, H., Niedobitek, G., Aloisi, F. & Middeldorp, J. M. Epstein–Barr virus in the multiple sclerosis brain: a controversial issue—report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 134, 2772–2786 (2011).

79 Hauser, S. L. et al. B-Cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).

80 Sundqvist, E. et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog. 10, e1004084 (2014).

81 Staras, S. A. et al. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin. Infect. Dis. 43, 1143–1151 (2006).

82 Waubant, E. et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76, 1989–1995 (2011).

83 Waubant, E. et al. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult. Scler. 19, 891–895 (2013).

84 Sundqvist, E. et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult. Scler. 20, 165–173 (2014).

85 Ascherio, A. et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083–3088 (2001).

86 Levin, L. I. et al. Temporal relationship between elevation of Epstein–Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496–2500 (2005).

87 DeLorenze, G. N. et al. Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63, 839–844 (2006).

88 Chidrawar, S. et al. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin. Exp. Immunol. 155, 423–432 (2009).

89 Munger, K. L. et al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann. Clin. Transl. Neurol. 1, 605–617 (2014).

90 Kampman, M. T., Wilsgaard, T. & Mellgren, S. I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 254, 471–477 (2007).

91 Baarnhielm, M. et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur. J. Neurol. 19, 955–962 (2012).

92 Becklund, B. R., Severson, K. S., Vang, S. V. & DeLuca, H. F. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc. Natl. Acad. Sci. U. S. A. 107, 6418–6423 (2010).

93 Rana, S., Rogers, L. J. & Halliday, G. M. Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am. J. Pathol. 178, 2783–2791 (2011).

94 Breuer, J. et al. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann. Neurol. 75, 739–758 (2014).

95 Navid, F. et al. The aryl hydrocarbon receptor is involved in UVR-induced immunosuppression. J. Invest. Dermatol. 133, 2763–2770 (2013).

96 Correale, J. & Farez, M. F. Modulation of multiple sclerosis by sunlight exposure: role of cis-urocanic acid. J. Neuroimmunol. 261, 134–140 (2013).

97 Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S. & Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832–2838 (2006).

98 Cortese, M. et al. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: the EnvIMS study. Mult. Scler. 21, 1856–1864 (2015).

99 Bjornevik, K. et al. Sun exposure and multiple sclerosis risk in Norway and Italy: the EnvIMS study. Mult. Scler. 20, 1042–1049 (2014).

100 Baarnhielm, M., Olsson, T. & Alfredsson, L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Mult. Scler. 20, 726–732 (2014).

101 Sandberg, L. et al. Vitamin D and axonal injury in multiple sclerosis. Mult. Scler. 22, 1027–1031 (2015).

102 Ueda, P. et al. Neonatal vitamin D status and risk of multiple sclerosis. Ann. Neurol. 76, 338–346 (2014).

103 Adzemovic, M. Z., Zeitelhofer, M., Hochmeister, S., Gustafsson, S. A. & Jagodic, M. Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammation depends on developmental stage. Exp. Neurol. 249, 39–48 (2013).

104 Munger, K. L. et al. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort. JAMA Neurol. 73, 515–519 (2016).

105 Staples, J., Ponsonby, A. L. & Lim, L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 340, c1640 (2010).

106 Sundqvist, E. et al. Confirmation of association between multiple sclerosis and CYP27B1. Eur. J. Hum. Genet. 18, 1349–1352 (2010).

107 Rhead, B. et al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol. Genet. 2, e97 (2016).

108 Mokry, L. E. et al. Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med. 12, e1001866 (2015).

109 Handunnetthi, L., Ramagopalan, S. V. & Ebers, G. C. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 74, 1905–1910 (2010).

110 Ascherio, A. et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 71, 306–314 (2014).

111 Fitzgerald, K. C. et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon Beta-1b. JAMA Neurol. 72, 1458–1465 (2015).

112 Munger, K. L., Chitnis, T. & Ascherio, A. Body size and risk of MS in two cohorts of US women. Neurology 73, 1543–1550 (2009).

113 Munger, K. L. et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult. Scler. 19, 1323–1329 (2013).

114 Hedstrom, A. K. et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 82, 865–872 (2014).

115 Gianfrancesco, M. A. et al. Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors. Obes. Res. Clin. Pract. 8, e435–447 (2014).

116 Langer-Gould, A., Brara, S. M., Beaber, B. E. & Koebnick, C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 80, 548–552 (2013).

117 Hedstrom, A. K., Olsson, T. & Alfredsson, L. Body mass index during adolescence, rather than childhood, is critical in determining MS risk. Mult. Scler. 22, 878–883 (2016).

118 Wesnes, K. et al. Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study. Mult. Scler. 21, 388–395 (2015).

119 Mokry, L. E. et al. Obesity and multiple sclerosis: a Mendelian randomization study. PLoS Med. 13, e1002053 (2016).

120 Gianfrancesco, M. A. et al. Genetic variants associated with body mass index demonstrate a causal effect on multiple sclerosis susceptibility. Am. J. Epidemiol. In press http://dx.doi.org/10.1093/aje/kww120 (2016).

121 Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175–184 (2007).

122 Procaccini, C., Pucino, V., Mantzoros, C. S. & Matarese, G. Leptin in autoimmune diseases. Metabolism 64, 92–104 (2015).

123 Matarese, G. et al. Leptin increase in multiple sclerosis associates with reduced number of CD4+CD25+ regulatory T cells. Proc. Natl Acad. Sci. USA. 102, 5150–5155 (2005).

124 Matarese, G., Carrieri, P. B., Montella, S., De Rosa, V. & La Cava, A. Leptin as a metabolic link to multiple sclerosis. Nat. Rev. Neurol. 6, 455–461 (2010).

125 Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z. & Holick, M. F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72, 690–693 (2000).

126 Karlsson, E. A. & Beck, M. A. The burden of obesity on infectious disease. Exp. Biol. Med. (Maywood) 235, 1412–1424 (2010).

127 Paich, H. A. et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity (Silver Spring) 21, 2377–2386 (2013).

128 Magrini, A. et al. Shift work and autoimmune thyroid disorders. Int. J. Immunopathol. Pharmacol. 19, 31–36 (2006).

129 Hedstrom, A. K., Akerstedt, T., Hillert, J., Olsson, T. & Alfredsson, L. Shift work at young age is associated with increased risk for multiple sclerosis. Ann. Neurol. 70, 733–741 (2011).

130 Hedstrom, A., Akerstedt, T., Olsson, T. & Alfredsson, L. Shift work influences multiple sclerosis risk. Mult. Scler. 21, 1195–1199 (2015).

131 Hansson, I., Holmdahl, R. & Mattsson, R. Constant darkness enhances autoimmunity to type II collagen and exaggerates development of collagen-induced arthritis in DBA/1 mice. J. Neuroimmunol. 27, 79–84 (1990).

132 Farez, M. F. et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162, 1338–1352 (2015).

133 Hansson, I., Holmdahl, R. & Mattsson, R. Pinealectomy ameliorates collagen II-induced arthritis in mice. Clin. Exp. Immunol. 92, 432–436 (1993).

134 Massa, J., O'Reilly, E. J., Munger, K. L. & Ascherio, A. Caffeine and alcohol intakes have no association with risk of multiple sclerosis. Mult. Scler. 19, 53–58 (2013).

135 Hedstrom, A. K., Hillert, J., Olsson, T. & Alfredsson, L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol. 71, 300–305 (2014).

136 Kallberg, H. et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann. Rheum. Dis. 68, 222–227 (2009).

137 Hedstrom, A. K. et al. High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies. J. Neurol. Neurosurg. Psychiatry 87, 454–460 (2016).

138 Chen, G. Q. et al. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res. 1309, 116–125 (2010).

139 Horrigan, L. A., Kelly, J. P. & Connor, T. J. Immunomodulatory effects of caffeine: friend or foe? Pharmacol. Ther. 111, 877–892 (2006).

140 Kleinewietfeld, M. et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496, 518–522 (2013).

141 Wu, C. et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496, 513–517 (2013).

142 Farez, M. F., Fiol, M. P., Gaitan, M. I., Quintana, F. J. & Correale, J. Sodium intake is associated with increased disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 86, 26–31 (2015).

143 Berer, K. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538–541 (2011).

144 Correale, J. & Farez, M. F. The impact of environmental infections (parasites) on MS activity. Mult. Scler. 17, 1162–1169 (2011).

145 Zhang, D. et al. Genetic control of individual differences in gene-specific methylation in human brain. Am. J. Hum. Genet. 86, 411–419 (2010).

146 Liu, Y. et al. GeMes, clusters of DNA methylation under genetic control, can inform genetic and epigenetic analysis of disease. Am. J. Hum. Genet. 94, 485–495 (2014).

147 Gao, X., Jia, M., Zhang, Y., Breitling, L. P. & Brenner, H. DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies. Clin. Epigenetics 7, 113 (2015).

148 Mastronardi, F. G. et al. Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J. Neurosci. 26, 11387–11396 (2006).

149 Baranzini, S. E. et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464, 1351–1356 (2010).

150 Pedre, X. et al. Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J. Neurosci. 31, 3435–3445 (2011).

151 Graves, M. C. et al. Methylation differences at the HLA-DRB1 locus in CD4+ T-Cells are associated with multiple sclerosis. Mult. Scler. 20, 1033–1041 (2014).

152 Huynh, J. L. et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat. Neurosci. 17, 121–130 (2014).

153 Bos, S. D. et al. Genome-wide DNA methylation profiles indicate CD8+ T cell hypermethylation in multiple sclerosis. PLoS ONE 10, e0117403 (2015).